メラノーマ治療薬の世界市場レポート 2025年

メラノーマ治療薬の市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR10.9％で68億4,000万米ドルに成長します。予測期間の成長は、新たな治療法、バイオマーカーの同定、イノベーションに対する規制当局の支援、個別化医療の進展、免疫療法の強化などに起因すると考えられます。予測期間の主な動向には、治療ガイドラインの進化、腫瘍学における遠隔医療、患者支援と意識向上、バイオマーカー研究、併用療法などが含まれます。

メラノーマの罹患率の上昇が、今後のメラノーマ治療薬市場の成長を牽引すると予測されます。メラノーマはメラノサイトから開発される皮膚がんの一種です。メラノーマ治療薬には、この疾患の患者を治療するために使用される治療法や薬剤が含まれ、がんの影響を緩和することを目的としています。そのため、メラノーマの罹患率の増加は、メラノーマ治療薬の売上増加に直接寄与しています。例えば、オーストラリア保健福祉研究所が2024年8月に発表した報告書によると、オーストラリアでは2034年までに約20万9,000人が新たにがんと診断されると予測されており、2024年に予測された16万9,000人から顕著に増加しています。さらに、2024年にはがんによる死亡が全死亡の約30％を占めると予想されています。このように、メラノーマの発生率の上昇がメラノーマ治療薬市場の成長を促進しています。

メラノーマ治療薬市場の成長は、高齢化人口の増加によって促進されると予測されます。高齢化とは、65歳以上の高齢者の割合が高くなる、または顕著に増加する人口動向として定義されます。メラノーマ治療薬は、この年齢層でメラノーマに対処するために使用されます。メラノーマはどの年齢でも発症する可能性のある皮膚がんですが、高齢になるにつれてますます罹患率が高くなります。これらの治療の実施には、患者の全身状態、メラノーマのステージ、既存の併存疾患など、いくつかの要因が影響します。例えば、2024年1月、統計の収集と提供を専門とする米国の非営利団体である人口問題研究所は、65歳以上の米国人の数が2022年の5,800万人から2050年には8,200万人になり、47％増加すると推定しています。さらに、総人口に占める65歳以上の高齢者の割合は、17％から23％に増加すると予想されています。その結果、高齢化人口の拡大がメラノーマ治療薬市場の発展に貢献しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のメラノーマ治療薬市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のメラノーマ治療薬市場：成長率分析
• 世界のメラノーマ治療薬市場の実績：規模と成長、2019～2024年
• 世界のメラノーマ治療薬市場の予測：規模と成長、2024～2029年、2034年
• 世界のメラノーマ治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のメラノーマ治療薬市場：薬の種類別、実績と予測、2019～2024年、2024～2029年、2034年
• モノクローナル抗体
• 低分子阻害剤
• その他
• 世界のメラノーマ治療薬市場：治療別、実績と予測、2019～2024年、2024～2029年、2034年
• 手術
• 放射線治療
• 免疫療法
• 標的療法
• 化学療法
• 世界のメラノーマ治療薬市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
• 経口
• 注射
• 世界のメラノーマ治療薬市場：がんの種類別、実績と予測、2019～2024年、2024～2029年、2034年
• 表在拡大型メラノーマ
• 結節型メラノーマ
• 悪性メラノーマ
• 末端黒子型メラノーマ
• 無色素性メラノーマ
• その他
• 世界のメラノーマ治療薬市場：診断別、実績と予測、2019～2024年、2024～2029年、2034年
• 皮膚鏡検査
• エンティネルリンパ節生検
• 血液検査
• X線検査
• 超音波検査
• CTスキャン
• 世界のメラノーマ治療薬市場：モノクローナル抗体のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• チェックポイント阻害剤
• 標的モノクローナル抗体
• 結合抗体
• 世界のメラノーマ治療薬市場：低分子阻害剤のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• BRAF阻害剤
• MEK阻害剤
• その他のキナーゼ阻害剤
• 世界のメラノーマ治療薬市場：その他のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 化学療法剤
• 免疫療法剤
• 補助療法

第7章 地域別・国別分析

• 世界のメラノーマ治療薬市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界のメラノーマ治療薬市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• メラノーマ治療薬市場：競合情勢
• メラノーマ治療薬市場：企業プロファイル
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• AB Science S.A
• Amgen Inc.
• Daiichi Sankyo Company Limited
• F. Hoffman-La Roche Ltd.
• Pfizer Inc.
• Bayer AG
• AbbVie Inc.
• Johnson & Johnson Private Limited
• The Bristol-Myers Squibb Company
• Nektar Therapeutics
• Immutep Ltd.
• Partner Therapeutics lnc.
• Idera Pharmaceuticals Inc.
• Oncolys BioPharma Inc.
• Iovance Biotherapeutics lnc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• メラノーマ治療薬市場2029年：新たな機会を提供する国
• メラノーマ治療薬市場2029年：新たな機会を提供するセグメント
• メラノーマ治療薬市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Melanoma therapeutics refer to treatment procedures employed for addressing melanoma, a form of skin cancer that originates in the melanocytes. These therapies operate by targeting abnormal cells, either by directly eliminating them or by impeding their growth and multiplication.

The primary categories of melanoma therapeutic drugs include monoclonal antibodies, small-molecule inhibitors, and others. Monoclonal antibodies are synthetic therapeutic proteins designed to bind to specific targets, such as antigens present in cancer cells, and are produced in laboratory settings. Various treatment modalities are encompassed, such as surgery, radiation therapy, immunotherapy, targeted therapy, and chemotherapy, and these therapies are administered through various routes, including oral and injectable methods. Melanoma is categorized into different types, including superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma, acral lentiginous melanoma, amelanotic melanoma, and others. Diagnosis involves techniques such as dermatoscopy, sentinel lymph node biopsy, blood tests, x-rays, ultrasound, and CT scans.

The melanoma therapeutics market research report is one of a series of new reports from The Business Research Company that provides melanoma therapeutics market statistics, including melanoma therapeutics industry global market size, regional shares, competitors with a melanoma therapeutics market share, detailed melanoma therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the melanoma therapeutics industry. This melanoma therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The melanoma therapeutics market size has grown rapidly in recent years. It will grow from$4.05 billion in 2024 to $4.51 billion in 2025 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to shift in treatment guidelines, increased awareness and early detection, regulatory approvals and clinical trials, evolution of combination therapies, advancements in surgical techniques

The melanoma therapeutics market size is expected to see rapid growth in the next few years. It will grow to $6.84 billion in 2029 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to emerging treatment modalities, biomarker identification, regulatory support for innovation, advancements in personalized medicine, immunotherapy enhancements. Major trends in the forecast period include evolving treatment guidelines, telemedicine in oncology, patient advocacy and awareness, biomarker research, combination therapies.

The rising incidence of melanoma is anticipated to drive the growth of the melanoma therapeutics market in the future. Melanoma is a type of skin cancer that develops from melanocytes. Melanoma therapeutics encompass the therapies and medications used to treat patients with this condition, aimed at alleviating the effects of cancer. As such, the growing incidence of melanoma directly contributes to increased sales of melanoma therapeutics. For instance, a report released by the Australian Institute of Health and Welfare in August 2024 indicates that Australia is projected to experience around 209,000 new cancer diagnoses by 2034, a notable rise from the estimated 169,000 cases expected in 2024, highlighting the influence of an expanding population and increasing cancer rates. Furthermore, cancer is expected to account for approximately 30% of all deaths in the country in 2024. Thus, the rising incidence of melanoma is propelling the growth of the melanoma therapeutics market.

The growth of the melanoma therapeutics market is anticipated to be fueled by the rising aging population. An aging population is defined as a demographic trend marked by a higher percentage or a notable rise in individuals aged 65 and older. Melanoma therapeutics are employed in this age group to address melanoma, a skin cancer that can develop at any age but becomes increasingly prevalent as people grow older. Several factors influence the administration of these treatments, including the patient's overall health, the stage of melanoma, and any existing comorbid conditions. For example, in January 2024, the Population Reference Bureau, a nonprofit organization in the US dedicated to collecting and providing statistics, estimated that the number of Americans aged 65 and older will rise from 58 million in 2022 to 82 million by 2050, representing a 47% increase. Additionally, the proportion of the total population represented by those aged 65 and older is expected to grow from 17% to 23%. Consequently, the expansion of the aging population is contributing to the development of the melanoma therapeutics market.

Product innovation is a notable trend gaining momentum in the melanoma therapeutics market, with major companies focusing on developing new and innovative therapies to strengthen their market position. In January 2022, Immunocore, a UK-based biotechnology company, successfully developed KIMMTRAK (tebentafusp-tebn), receiving FDA approval for the treatment of metastatic uveal melanoma. KIMMTRAK is a groundbreaking bispecific protein with anti-CD3 immune-effector activity linked to a soluble T cell receptor, demonstrating an overall survival of nearly 22 months in a successful phase 3 clinical trial. This represents the first compound created using Immunocore's ImmTAC technology platform, redirecting and activating T lymphocytes to identify and eliminate tumor cells.

Major companies in the melanoma therapeutics market are introducing innovative products such as Opdualag to enhance their market profitability. Opdualag, a medication for the treatment of melanoma that has spread or cannot be surgically removed, was approved by the FDA in March 2022. Developed by Bristol Myers Squibb, Opdualag is a breakthrough combination therapy targeting both PD-1 and LAG-3, improving efficacy and tolerability compared to current immunotherapies. This provides a novel treatment option for advanced melanoma patients, enhancing the effectiveness of existing immunotherapies without significantly increasing side effects.

In April 2022, EMZ Partners, a Germany-based investment firm, acquired a majority stake in FotoFinder Systems GmbH for an undisclosed amount. This strategic partnership is expected to enable FotoFinder Systems GmbH to expand its product offerings and reach new markets. FotoFinder Systems GmbH, based in Germany, provides skin visualization equipment used in melanoma therapeutics.

Major companies operating in the melanoma therapeutics market include AstraZeneca plc, Eli Lilly and Company, Merck & Co. Inc., Novartis AG, Sanofi S.A., AB Science S.A, Amgen Inc., Daiichi Sankyo Company Limited, F. Hoffman-La Roche Ltd., Pfizer Inc., Bayer AG, AbbVie Inc., Johnson & Johnson Private Limited, The Bristol-Myers Squibb Company, Nektar Therapeutics, Immutep Ltd., Partner Therapeutics lnc., Idera Pharmaceuticals Inc., Oncolys BioPharma Inc., Iovance Biotherapeutics lnc., AIM ImmunoTech Inc., Infinity Pharmaceuticals lnc., Spring Bank Pharmaceuticals lnc., Incyte Corporation, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Eisai Co.Ltd., Seattle Genetics Inc., Regeneron Pharmaceuticals Inc., Bio-Rad Laboratories Inc., Myriad Genetics Inc.

North America was the largest region in the melanoma therapeutics market in 2024. The regions covered in the melanoma therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the melanoma therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The melanoma therapeutics market includes revenues earned by entities by providing stereotactic radiosurgery, stereotactic ablative radiation therapy, intralesional therapy, and palliative therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Melanoma Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on melanoma therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for melanoma therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The melanoma therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Monoclonal Antibodies; Small Molecule Inhibitors; Other Drug Types
• 2) By Therapy: Surgery; Radiation Therapy; Immunotherapy; Targeted Therapy; Chemotherapy
• 3) By Route of administration: Oral; Injectable
• 4) By Cancer Type: Superficial Spreading Melanoma; Nodular Melanoma; Lentigo Maligna Melanoma; Acral Lentiginous Melanoma; Amelanotic Melanoma; Other Cancer Types
• 5) By Diagnosis: Dermatoscopy; Sentinel Lymph Node Biopsy; Blood Test; X-ray; Ultrasound; CT Scan
• Subsegments:
• 1) By Monoclonal Antibodies: Checkpoint Inhibitors; Targeted Monoclonal Antibodies; Conjugated Antibodies
• 2) By Small Molecule Inhibitors: BRAF Inhibitors; MEK Inhibitors; Other Kinase Inhibitors
• 3) By Other Drug Types: Chemotherapy Agents; Immunotherapy Agents; Adjuvant Therapies
• Companies Mentioned: AstraZeneca plc; Eli Lilly and Company; Merck & Co. Inc.; Novartis AG; Sanofi S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Melanoma Therapeutics Market Characteristics

3. Melanoma Therapeutics Market Trends And Strategies

4. Melanoma Therapeutics Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Melanoma Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Melanoma Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Melanoma Therapeutics Market Growth Rate Analysis
• 5.4. Global Melanoma Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Melanoma Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Melanoma Therapeutics Total Addressable Market (TAM)

6. Melanoma Therapeutics Market Segmentation

• 6.1. Global Melanoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• Small Molecule Inhibitors
• Other Drug Types
• 6.2. Global Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Surgery
• Radiation Therapy
• Immunotherapy
• Targeted Therapy
• Chemotherapy
• 6.3. Global Melanoma Therapeutics Market, Segmentation By Route of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• 6.4. Global Melanoma Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Superficial Spreading Melanoma
• Nodular Melanoma
• Lentigno Maligna Melanoma
• Acral Lentiginous Melanoma
• Amelanotic Melanoma
• Other Cancer Types
• 6.5. Global Melanoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dermatoscopy
• Entinel Lymph Node Biopsy
• Blood Test
• X-ray
• Ultrasound
• CT Scan
• 6.6. Global Melanoma Therapeutics Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Checkpoint Inhibitors
• Targeted Monoclonal Antibodies
• Conjugated Antibodies
• 6.7. Global Melanoma Therapeutics Market, Sub-Segmentation Of Small Molecule Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• BRAF Inhibitors
• MEK Inhibitors
• Other Kinase Inhibitors
• 6.8. Global Melanoma Therapeutics Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy Agents
• Immunotherapy Agents
• Adjuvant Therapies

7. Melanoma Therapeutics Market Regional And Country Analysis

• 7.1. Global Melanoma Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Melanoma Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Melanoma Therapeutics Market

• 8.1. Asia-Pacific Melanoma Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Melanoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Melanoma Therapeutics Market, Segmentation By Route of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Melanoma Therapeutics Market

• 9.1. China Melanoma Therapeutics Market Overview
• 9.2. China Melanoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Melanoma Therapeutics Market, Segmentation By Route of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Melanoma Therapeutics Market

• 10.1. India Melanoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Melanoma Therapeutics Market, Segmentation By Route of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Melanoma Therapeutics Market

• 11.1. Japan Melanoma Therapeutics Market Overview
• 11.2. Japan Melanoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Melanoma Therapeutics Market, Segmentation By Route of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Melanoma Therapeutics Market

• 12.1. Australia Melanoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Melanoma Therapeutics Market, Segmentation By Route of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Melanoma Therapeutics Market

• 13.1. Indonesia Melanoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Melanoma Therapeutics Market, Segmentation By Route of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Melanoma Therapeutics Market

• 14.1. South Korea Melanoma Therapeutics Market Overview
• 14.2. South Korea Melanoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Melanoma Therapeutics Market, Segmentation By Route of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Melanoma Therapeutics Market

• 15.1. Western Europe Melanoma Therapeutics Market Overview
• 15.2. Western Europe Melanoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Melanoma Therapeutics Market, Segmentation By Route of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Melanoma Therapeutics Market

• 16.1. UK Melanoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Melanoma Therapeutics Market, Segmentation By Route of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Melanoma Therapeutics Market

• 17.1. Germany Melanoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Melanoma Therapeutics Market, Segmentation By Route of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Melanoma Therapeutics Market

• 18.1. France Melanoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Melanoma Therapeutics Market, Segmentation By Route of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Melanoma Therapeutics Market

• 19.1. Italy Melanoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Melanoma Therapeutics Market, Segmentation By Route of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Melanoma Therapeutics Market

• 20.1. Spain Melanoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Melanoma Therapeutics Market, Segmentation By Route of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Melanoma Therapeutics Market

• 21.1. Eastern Europe Melanoma Therapeutics Market Overview
• 21.2. Eastern Europe Melanoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Melanoma Therapeutics Market, Segmentation By Route of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Melanoma Therapeutics Market

• 22.1. Russia Melanoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Melanoma Therapeutics Market, Segmentation By Route of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Melanoma Therapeutics Market

• 23.1. North America Melanoma Therapeutics Market Overview
• 23.2. North America Melanoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Melanoma Therapeutics Market, Segmentation By Route of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Melanoma Therapeutics Market

• 24.1. USA Melanoma Therapeutics Market Overview
• 24.2. USA Melanoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Melanoma Therapeutics Market, Segmentation By Route of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Melanoma Therapeutics Market

• 25.1. Canada Melanoma Therapeutics Market Overview
• 25.2. Canada Melanoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Melanoma Therapeutics Market, Segmentation By Route of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Melanoma Therapeutics Market

• 26.1. South America Melanoma Therapeutics Market Overview
• 26.2. South America Melanoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Melanoma Therapeutics Market, Segmentation By Route of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Melanoma Therapeutics Market

• 27.1. Brazil Melanoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Melanoma Therapeutics Market, Segmentation By Route of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Melanoma Therapeutics Market

• 28.1. Middle East Melanoma Therapeutics Market Overview
• 28.2. Middle East Melanoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Melanoma Therapeutics Market, Segmentation By Route of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Melanoma Therapeutics Market

• 29.1. Africa Melanoma Therapeutics Market Overview
• 29.2. Africa Melanoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Melanoma Therapeutics Market, Segmentation By Route of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Melanoma Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Melanoma Therapeutics Market Competitive Landscape
• 30.2. Melanoma Therapeutics Market Company Profiles
  • 30.2.1. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Melanoma Therapeutics Market Other Major And Innovative Companies

• 31.1. AB Science S.A
• 31.2. Amgen Inc.
• 31.3. Daiichi Sankyo Company Limited
• 31.4. F. Hoffman-La Roche Ltd.
• 31.5. Pfizer Inc.
• 31.6. Bayer AG
• 31.7. AbbVie Inc.
• 31.8. Johnson & Johnson Private Limited
• 31.9. The Bristol-Myers Squibb Company
• 31.10. Nektar Therapeutics
• 31.11. Immutep Ltd.
• 31.12. Partner Therapeutics lnc.
• 31.13. Idera Pharmaceuticals Inc.
• 31.14. Oncolys BioPharma Inc.
• 31.15. Iovance Biotherapeutics lnc.

32. Global Melanoma Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Melanoma Therapeutics Market

34. Recent Developments In The Melanoma Therapeutics Market

35. Melanoma Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Melanoma Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Melanoma Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Melanoma Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer